AI Engines For more Details: Perplexity Kagi Labs You
Limited Research in Humans: There is scarce research available on the health impacts of 6-FA in humans, particularly as a non-drug compound. Most of the research on 6-FA has focused on its agricultural applications and its effects on plant physiology.
Potential Effects on Cell Growth: As a cytokinin analog, 6-FA may have potential effects on cell growth and proliferation. Cytokinins are known to stimulate cell division and promote growth in plants. In theory, 6-FA could influence cell growth processes in humans, although the specific mechanisms and effects are not well understood.
Safety Concerns: Due to the limited research available, the safety profile of 6-FA in humans is not well-established. It is unclear whether 6-FA has any adverse effects or toxicity when consumed or exposed to humans. As with any synthetic chemical, there may be potential safety concerns associated with its use, particularly at higher doses or with long-term exposure.
Potential for Pharmacological Use: While 6-FA is primarily used in agriculture, there is some interest in exploring its potential pharmacological applications. Cytokinins have been studied for their potential therapeutic effects in various medical conditions, including neurodegenerative disorders, cancer, and aging-related conditions. However, research on the pharmacological properties of 6-FA in humans is limited, and further studies are needed to evaluate its efficacy and safety.
Regulatory Status: The regulatory status of 6-FA may vary depending on its intended use and jurisdiction. In some countries, it may be regulated as an agricultural chemical, while in others, it may be subject to regulations governing chemical safety and environmental protection. The use of 6-FA in non-agricultural settings may be subject to regulatory oversight to ensure safety and compliance with applicable laws and regulations.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.7 | 0.4 | 0.75 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0 | 0 |
Allergic Rhinitis (Hay Fever) | 1.2 | 1.2 | |
Allergies | 1.5 | 0.4 | 2.75 |
Allergy to milk products | 1 | 0.4 | 1.5 |
Alzheimer's disease | 1.3 | 2.6 | -1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 0.8 | 0.75 |
Ankylosing spondylitis | 1.1 | 0.9 | 0.22 |
Anorexia Nervosa | 0 | 0.8 | 0 |
Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
Asthma | 0.2 | 0.2 | 0 |
Atherosclerosis | 0.2 | 0.3 | -0.5 |
Atrial fibrillation | 1.1 | 0.5 | 1.2 |
Autism | 2.2 | 2.6 | -0.18 |
Barrett esophagus cancer | 0.1 | -0.1 | |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 0.7 | 0.7 | 0 |
Brain Trauma | 0.2 | -0.2 | |
Carcinoma | 0.8 | 0.3 | 1.67 |
Celiac Disease | 0.9 | 0.3 | 2 |
Cerebral Palsy | 0.1 | 0.4 | -3 |
Chronic Fatigue Syndrome | 1.7 | 1.3 | 0.31 |
Chronic Kidney Disease | 1.3 | 1.2 | 0.08 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.5 | -1.5 |
Chronic Urticaria (Hives) | 1.1 | 0.7 | 0.57 |
Coagulation / Micro clot triggering bacteria | 1.1 | 0.3 | 2.67 |
Colorectal Cancer | 2.1 | 0.4 | 4.25 |
Constipation | 0.5 | 0.1 | 4 |
Coronary artery disease | 1.1 | 0.4 | 1.75 |
COVID-19 | 1.8 | 2.6 | -0.44 |
Crohn's Disease | 3.2 | 2.2 | 0.45 |
cystic fibrosis | 1 | 0.2 | 4 |
deep vein thrombosis | 1 | 0.3 | 2.33 |
Depression | 2.5 | 3.4 | -0.36 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 1 | 0.8 | 0.25 |
Endometriosis | 1.6 | 0.2 | 7 |
Epilepsy | 1.2 | 0.2 | 5 |
Fibromyalgia | 0.2 | 0.9 | -3.5 |
Functional constipation / chronic idiopathic constipation | 2.3 | 1.4 | 0.64 |
gallstone disease (gsd) | 0.6 | 0.1 | 5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.1 | 6 |
Generalized anxiety disorder | 1.6 | 0.5 | 2.2 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0.4 | -0.4 | |
Graves' disease | 0.2 | 0.1 | 1 |
Halitosis | 0.1 | 0.1 | 0 |
Hashimoto's thyroiditis | 0.3 | 0.1 | 2 |
Hidradenitis Suppurativa | 0.1 | 0.1 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.3 | 0.5 | 1.6 |
hypercholesterolemia (High Cholesterol) | 0 | 0 | |
hyperglycemia | 0.3 | 0.2 | 0.5 |
hypertension (High Blood Pressure | 0.7 | 1.3 | -0.86 |
Hypothyroidism | 0.4 | -0.4 | |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 0.8 | -0.8 | |
Inflammatory Bowel Disease | 2.6 | 3 | -0.15 |
Insomnia | 0.2 | 0.2 | 0 |
Intelligence | 0.4 | 0.4 | |
Intracranial aneurysms | 0.3 | 0.3 | |
Irritable Bowel Syndrome | 1.5 | 0.4 | 2.75 |
Liver Cirrhosis | 1.2 | 0.8 | 0.5 |
Long COVID | 2.4 | 1.4 | 0.71 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.4 | 0.2 | 1 |
ME/CFS with IBS | 0.1 | 0.9 | -8 |
ME/CFS without IBS | 1.1 | 0.1 | 10 |
Menopause | 0.1 | 0.1 | |
Metabolic Syndrome | 3.3 | 1.5 | 1.2 |
Mood Disorders | 3.1 | 3.5 | -0.13 |
multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
Multiple Sclerosis | 0.6 | 2 | -2.33 |
Multiple system atrophy (MSA) | 0.1 | 0.2 | -1 |
Neuropathy (all types) | 0.1 | 0.3 | -2 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 1.4 | -2.5 |
Obesity | 2 | 1.1 | 0.82 |
obsessive-compulsive disorder | 2.4 | 1.6 | 0.5 |
Osteoarthritis | 1.2 | 0.2 | 5 |
Osteoporosis | 0.7 | 0.1 | 6 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 1.2 | 2.2 | -0.83 |
Polycystic ovary syndrome | 0.7 | 0.4 | 0.75 |
Postural orthostatic tachycardia syndrome | 0 | 0.4 | 0 |
Premenstrual dysphoric disorder | 0 | 0 | |
Psoriasis | 1.6 | 0.6 | 1.67 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 1.3 | 0.46 |
Rosacea | 0.3 | 0.1 | 2 |
Schizophrenia | 0.9 | 0.7 | 0.29 |
scoliosis | 0.4 | 0.2 | 1 |
Sjögren syndrome | 0.4 | 0.5 | -0.25 |
Sleep Apnea | 0.5 | 0.7 | -0.4 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | |
Stress / posttraumatic stress disorder | 1 | 0.7 | 0.43 |
Systemic Lupus Erythematosus | 2.3 | 0.2 | 10.5 |
Tic Disorder | 0.2 | 0.2 | |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 1.8 | 0.2 | 8 |
Type 2 Diabetes | 3.2 | 2.2 | 0.45 |
Ulcerative colitis | 1.4 | 0.8 | 0.75 |
Unhealthy Ageing | 2.1 | 1.2 | 0.75 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.